Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
President & Chief Executive Officer
Josh joined Oncocyte Corporation in August 2020 and was appointed Interim Chief Executive Officer in December 2022, after serving as Senior Director Business Development and General Manager, Transplant.
Josh is an experienced business leader and was previously the founder and principal of Intelliger Consulting, an organization devoted to consumer driven healthcare, and a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.
Prof. Dr. Ekkehard Schütz, MD, PhD, FAACC
Chief Science Officer
Ekkehard (Ekke) joined Oncocyte in April 2021 through the acquisition of Chronix Biomedical. Ekke serves as the managing director of Chronix Biomedical GmbH, wholly owned by Oncocyte and CMO for Europe. As an adjunct professor, he teaches molecular genetics and diagnostics at the Georg-August-University.
Ekke received his training in laboratory medicine (chemical pathology) at the Dept. of Clinical Chemistry in the hospital of the Georg-August-University of Göttingen, where he worked from 1989 to 2001 under Prof. Dr. Michael Oellerich, a world expert in therapeutic drug monitoring and transplantation surveillance. He joined Chronix Biomedical Inc. (San Jose, CA) in 2001. He established its German subsidiary in 2002 as the R&D site of the company. Chronix became an industry leader in cell-free DNA (cf-DNA) diagnostics, which resulted in numerous scientific publications and a broad patent portfolio in cf-DNA diagnostics in cancer and transplantation with ten different patent families and multiple issued IP in the US and Europe of which Ekke is the inventor.
In 2014 was elected as a fellow of the National Academy for Clinical Biochemistry, which became the Academy of the American Association for Clinical Chemistry (FAACC). Besides his broad experience in patenting, Ekke has published over 170 peer-reviewed publications and book chapters, over 100 published congress abstracts, has received several international scientific awards, and serves as a reviewer for numerous international scientific journals, including PNAS, Clin Chem, Clin Biochem and NAR.
Yuh-Min (Johnson) Chiang, PhD
Chief Technology Officer
Johnson joined Oncocyte Corporate in September 2021. Prior to joining Oncocyte, Johnson holds the Chief Technology Officer in Alveo Technologies, an IVD company focusing on development of cutting edge molecular diagnostic tests for Over The Counter (OTC) and Point-Of-Care (POC) applications. Johnson led the teams to develop the COVID-19 be.well Test for a successful US clinical trial and obtained the CE mark and UK approval.
At Alveo, Johnson also participated in fundraising of about $50MM in 4 years, including winning the XPrize Grand Award for Rapid Covid Testing Competition. Before Alveo Technologies, Johnson was the Head of Systems Integration & Molecular Biology at Foundation Medicine, Inc. and held senior management positions at Life Technologies and Thermo Fisher Scientific where he led systems design, integration, verification and validation for qPCR and next-generation sequencing platforms, including Oncomine Dx Target Test as the very first NGS-based CDx test approved by FDA. Johnson also worked at Cepheid where he oversaw a few key product developments from the concept to commercialization under FDA regulation. He has extensive experience and successful track records in product development (device, instrument, SW, and assays) as well as design control for 510k and PMA applications. Johnson also owns several patents and published numerous biotechnology papers.
Johnson holds a Ph.D. degree focused on BioMEMS (Micro Electro-Mechanical Systems) from University of California, Irvine. He received his Master in Engineering from The Ohio State University and Bachelor of Applied Chemistry from National Chiao Tung University, Taiwan.
Senior Vice President, Business Operations
Sandra joined Oncocyte Corporation in December 2019 and was appointed SVP, Business Operations, after serving as VP, Operations & PMO, and Director of PMO.
She brings over 20 years of experience by combining a business management background with strategy, operations, P&L, commercialization, and integration experience.
Leadership roles include consumer products company Georgia Pacific LLC, wastepaper recycling company Harmon Associates, and food manufacturing company Corbin Foods. She has led large-scale change management to drive a capability operational model, as well as, small- to mid-size company scaling and integration strategies.
Sandra is known for her solution-based approach and practical ideas with a focus on continuous business improvement and operational excellence.
Vice President, Commercial
Ryan joined Oncocyte Corporation in August 2019 and was appointed VP, Commercial after serving as Sr. Director, Marketing and Director of Marketing. Prior to joining Oncocyte, Ryan was principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.
At Bethesda Group, Ryan was responsible for working with clients to identify market entry points, quantify market opportunities for products, market landscape analysis, and development of commercial strategy and go to market planning. Before Bethesda Group, Ryan held roles in sales, marketing, and operations at ThermoFisher Scientific, LifeTechnologies and Cytovance Biologics. Ryan received his MBA and Bachelors in Finance from The University of Mississippi.
Vice President, General Counsel
Peter joined Oncocyte in August 2021 as Vice President, General Counsel. Prior to joining Oncocyte, Peter was an associate at Stradling Yocca Carlson & Rauth, P.C. where he represented public and private companies in capital markets, M&A and corporate governance matters. Before joining Stradling, Peter was an associate at the New York office of Covington & Burling LLP where he represented underwriters in the initial public offerings and follow-on offerings of biotechnology companies.
At Covington, Peter also advised overseas clients with regard to restructuring, employment matters and the formation of U.S. subsidiaries. Peter received a J.D. from Columbia Law School and a B.S. degree in Business Administration from Washington University in St. Louis. He is admitted to practice law in New York and California.
Senior Director, Controller & Principal Accounting Officer
James joined Oncocyte Corporation in July 2021 and was appointed Senior Director, Controller & Principal Accounting Officer in August 2023 after previously serving as the Company’s Manager of Securities and Exchange Commission Reporting & Compliance from July 2021 to July 2022, as interim Controller from July 2022 to September 2022, and as Controller & Principal Accounting Officer from July 2022 to August 2023. Additionally, James was appointed to the additional role of interim Principal Financial Officer in August 2023.
Prior to that, James was the Accounting Manager of Acacia Research Corporation, an opportunistic capital platform that identifies and acquires other businesses, from November 2020 to July 2021, and Senior Accountant at Gatekeeper Systems, Inc., a provider of loss prevention solutions, from August 2019 to November 2020. Prior to joining Gatekeeper Systems, James served as Senior Assurance Associate at BDO USA, LLP, an accounting firm, from October 2016 to August 2019. James holds a BASc degree from the University of California, San Diego, and is a Certified Public Accountant.